Skeletal metastases are frequent complications of many cancers, causing bone
complications (fractures, bone pain, disability) that negatively affect the patient's quality of …

As one of the most common metastatic sites of malignancies, bone has a unique
microenvironment that allows metastatic tumor cells to grow and flourish. The fenestrated …

In patients with prostate cancer (PCa), bone lesions appear osteoblastic in radiographs;
however, pathological fractures frequently occur in PCa patients, and bone resorption is …

The incidence of aggressive neuroendocrine prostate cancers (NEPC) related to androgen-
deprivation therapy (ADT) is rising. NEPC is still poorly understood, such as its …

Bone morphogenetic proteins (BMPs) are a diverse class of molecules with over 20 growth
factor proteins that belong to the transforming growth factor-β (TGF-β) family and are highly …

Prostate cancer antigen 3 (PCA3) is the most specific prostate cancer biomarker but its
function remains unknown. Here we identify PRUNE2, a target protein-coding gene variant …

While the antiandrogen enzalutamide (Enz) extends the castration resistant prostate cancer
(CRPC) patients' survival an extra 4.8 months, it might also result in some adverse effects via …

Growth factor signaling pathways are tightly regulated by phosphorylation and include many
important kinase targets of interest for drug discovery. Small molecule inhibitors of the bone …

Bone morphogenetic proteins (BMPs) are secreted cytokines that control the fate and
function of many different cell types. They exert their cellular responses via heteromeric …

Bioinformatic analysis of 94 patient-derived xenografts (PDXs), cell lines, and organoids
(PCOs) identifies three intrinsic transcriptional subtypes of metastatic castration-resistant …